Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04437225

Renal Metabolism of Glycolate to Oxalate

This study will determine the contribution of glycolate metabolism to urinary oxalate excretion in healthy subjects, using carbon 13 isotope glycolate tracer technique and a low-oxalate controlled diet.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

About this study

It is known that glycolate, an intermediary molecule in normal metabolism, can be converted into oxalate. The origin of urinary oxalate is of interest as calcium oxalate is a main component of kidney stones. In the rare disease primary hyperoxaluria, excessive production of oxalate by the body results in frequent kidney stones and can cause loss of kidney function. Primary hyperoxaluria is caused by deficiencies in one of several enzymes involved in the glycolate pathway.

This study will seek to determine how much oxalate is formed from glycolate in normal subjects. After consuming a controlled diet, subjects will either ingest or have an intravenous infusion of carbon 13 glycolate, a stable isotope of glycolate that can be tracked and will also label downstream metabolic products. Blood and urine samples will be assessed for their amounts of labeled glycolate and labeled oxalate to provide an accurate measure of how much oxalate is made from normal glycolate breakdown in healthy human subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mentally competent adults, able to read and comprehend the consent form
  • 18-75 years of age
  • Body Mass Index (BMI) between 19 and 40
  • In good health as judged from a medical history, reported medications, and a complete blood metabolic profile
  • Acceptable 24 hour urine collections (performed twice for screening)

Exclusion criteria

  • History of any hepatic, renal, bowel, or endocrine disease or any other condition that may influence the absorption, transport or urine excretion of ions
  • Abnormal urine chemistries or blood metabolic profiles
  • Poor 24 hour urine collections completed during screening, judged by 24 hour urine creatinine excretion (indicative of not collecting all urine in the 24 hour period)
  • Pregnancy, intention to become pregnant in the near future, or lactation
  • Aged <18 or >75
  • BMI <19 or >40

Treatment and study plan

Low oxalate controlled Diet

Dietary Supplement

Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Primed, continuous intravenous infusion of 13C2-Glycolate

Other

Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.

Other names: Constant infusion of 13C2-Glycolate

Bolus intravenous infusion of 13C2-Glycolate

Other

Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.

Other names: Single intravenous dose of 13C2-Glycolate

Oral bolus administration of 13C2-Glycolate

Other

Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.

Other names: Single oral dose of 13C2-Glycolate

Primary outcomes

  1. Urinary oxalate measured by ion chromatography coupled with mass spectrometry

    Time frame: day 5 of dietary control

    Measurement of carbon 13 labeled and unlabeled urinary oxalate following carbon 13 glycolate administration, after equilibration under a low-oxalate diet.

  2. Plasma glycolate measured by ion chromatography coupled with mass spectrometry

    Time frame: day 5 of dietary control

    Measurement of carbon 13 labeled and unlabeled plasma glycolate following carbon 13 glycolate administration, after equilibration under a low-oxalate diet.

Secondary outcomes

  1. Urinary creatinine

    Time frame: day 5 of dietary control

    Baseline assessment of 24hr urinary creatinine under controlled low-oxalate diet.

  2. Urinary glycolate measured by ion chromatography coupled with mass spectrometry

    Time frame: day 5 of dietary control

    Measurement of carbon 13 labeled and unlabeled urinary glycolate following carbon 13 glycolate administration, after equilibration under a low-oxalate diet.

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Important dates

Study start
2020
Primary completion
2026
Study completion
2027
First posted
Jun 18, 2020
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.